Dendreon Announces Webcast Presentations at Upcoming Investor Conferences

SEATTLE, April 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following investor conferences in May.

The following presentations will be webcast:


Deutsche Bank 35th Annual Health Care Conference, Boston, MA

May 3, 2010

10:40 a.m. ET


Bank of America Merrill Lynch 2010 Health Care Conference, New York, NY

May 11, 2010

2:20 p.m. ET


Citi 2010 Global Health Care Conference, New York, NY

May 26, 2010

8:00 a.m. ET



The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.  

In addition, Dendreon will participate at:


Brean Murray, Carret & Co. 2010 Life Sciences Summit, New York, NY

May 17, 2010



Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

SOURCE Dendreon Corporation

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.